403 related articles for article (PubMed ID: 33247955)
1. Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial.
Ohsawa I; Honda D; Suzuki Y; Fukuda T; Kohga K; Morita E; Moriwaki S; Ishikawa O; Sasaki Y; Tago M; Chittick G; Cornpropst M; Murray SC; Dobo SM; Nagy E; Van Dyke S; Reese L; Best JM; Iocca H; Collis P; Sheridan WP; Hide M
Allergy; 2021 Jun; 76(6):1789-1799. PubMed ID: 33247955
[TBL] [Abstract][Full Text] [Related]
2. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial.
Zuraw B; Lumry WR; Johnston DT; Aygören-Pürsün E; Banerji A; Bernstein JA; Christiansen SC; Jacobs JS; Sitz KV; Gower RG; Gagnon R; Wedner HJ; Kinaciyan T; Hakl R; Hanzlíková J; Anderson JT; McNeil DL; Fritz SB; Yang WH; Tachdjian R; Busse PJ; Craig TJ; Li HH; Farkas H; Best JM; Clemons D; Cornpropst M; Dobo SM; Iocca HA; Kargl D; Nagy E; Murray SC; Collis P; Sheridan WP; Maurer M; Riedl MA
J Allergy Clin Immunol; 2021 Jul; 148(1):164-172.e9. PubMed ID: 33098856
[TBL] [Abstract][Full Text] [Related]
3. Once-Daily Oral Berotralstat for Long-Term Prophylaxis of Hereditary Angioedema: The Open-Label Extension of the APeX-2 Randomized Trial.
Kiani-Alikhan S; Gower R; Craig T; Wedner HJ; Kinaciyan T; Aygören-Pürsün E; Banerji A; Bernstein JA; Anderson J; Collis P; Johnston DT; Desai B; Tomita D; Gagnon R; Tachdjian R; Soteres DF; Farkas H; Caballero T; McNeil D; Jacobs J; Lumry WR;
J Allergy Clin Immunol Pract; 2024 Mar; 12(3):733-743.e10. PubMed ID: 38122865
[TBL] [Abstract][Full Text] [Related]
4. Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2).
Wedner HJ; Aygören-Pürsün E; Bernstein J; Craig T; Gower R; Jacobs JS; Johnston DT; Lumry WR; Zuraw BL; Best JM; Iocca HA; Murray SC; Desai B; Nagy E; Sheridan WP; Kiani-Alikhan S
J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2305-2314.e4. PubMed ID: 33866032
[TBL] [Abstract][Full Text] [Related]
5. Berotralstat (BCX7353) is a novel oral prophylactic treatment for hereditary angioedema: Review of phase II and III studies.
Manning ME; Kashkin JM
Allergy Asthma Proc; 2021 Jul; 42(4):274-282. PubMed ID: 34127176
[No Abstract] [Full Text] [Related]
6. Long-term safety and effectiveness of berotralstat for hereditary angioedema: The open-label APeX-S study.
Farkas H; Stobiecki M; Peter J; Kinaciyan T; Maurer M; Aygören-Pürsün E; Kiani-Alikhan S; Wu A; Reshef A; Bygum A; Fain O; Hagin D; Huissoon A; Jeseňák M; Lindsay K; Panovska VG; Steiner UC; Zubrinich C; Best JM; Cornpropst M; Dix D; Dobo SM; Iocca HA; Desai B; Murray SC; Nagy E; Sheridan WP
Clin Transl Allergy; 2021 Jun; 11(4):e12035. PubMed ID: 34161665
[TBL] [Abstract][Full Text] [Related]
7. Berotralstat for long-term prophylaxis of hereditary angioedema in Japan: Parts 2 and 3 of the randomized APeX-J Phase III trial.
Honda D; Hide M; Fukuda T; Koga K; Morita E; Moriwaki S; Sasaki Y; Suzuki Y; Collis P; Johnston DT; Tomita D; Desai B; Ohsawa I
World Allergy Organ J; 2024 Mar; 17(3):100882. PubMed ID: 38445295
[TBL] [Abstract][Full Text] [Related]
8. Orladeyo (Berotralstat): A Novel Oral Therapy for the Prevention of Hereditary Angioedema.
Powell J; Piszczatoski C; Rubido E
Ann Pharmacother; 2022 Apr; 56(4):488-493. PubMed ID: 34282650
[TBL] [Abstract][Full Text] [Related]
9. A Retrospective Analysis of Long-Term Prophylaxis with Berotralstat in Patients with Hereditary Angioedema and Acquired C1-Inhibitor Deficiency-Real-World Data.
Johnson F; Stenzl A; Hofauer B; Heppt H; Ebert EV; Wollenberg B; Lochbaum R; Hahn J; Greve J; Trainotti S
Clin Rev Allergy Immunol; 2023 Dec; 65(3):354-364. PubMed ID: 37914894
[TBL] [Abstract][Full Text] [Related]
10. Interventions for the long-term prevention of hereditary angioedema attacks.
Beard N; Frese M; Smertina E; Mere P; Katelaris C; Mills K
Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013403. PubMed ID: 36326435
[TBL] [Abstract][Full Text] [Related]
11. A review of berotralstat for the treatment of hereditary angioedema.
Farkas H; Balla Z
Expert Rev Clin Immunol; 2023 Feb; 19(2):145-153. PubMed ID: 36408587
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacological and clinical study results of Berotralstat Hydrochloride for long-term prophylactic treatment of hereditary angioedema].
Orui S; Nozue H; Kobayashi S; Fujioka M; Maekawa Y
Nihon Yakurigaku Zasshi; 2021; 156(6):382-390. PubMed ID: 34719573
[TBL] [Abstract][Full Text] [Related]
13. A review of oral kallikrein inhibitor berotralstat for hereditary angioedema.
Gao Y; Hwang J; Hwang G; Craig T
Drugs Today (Barc); 2022 Feb; 58(2):59-67. PubMed ID: 35188140
[TBL] [Abstract][Full Text] [Related]
14. Hereditary angioedema outcomes in US patients switched from injectable long-term prophylactic medication to oral berotralstat.
Riedl MA; Soteres D; Sublett JW; Desai B; Tomita D; Collis P; Bernstein JA;
Ann Allergy Asthma Immunol; 2024 Apr; 132(4):505-511.e1. PubMed ID: 38006972
[TBL] [Abstract][Full Text] [Related]
15. Berotralstat in hereditary angioedema due to C1 inhibitor deficiency: first real-world evidence from a Canadian center.
Srinivasan C; Ritchie B; Adatia A
Front Immunol; 2024; 15():1339421. PubMed ID: 38318176
[TBL] [Abstract][Full Text] [Related]
16. Berotralstat: First Approval.
Lee A
Drugs; 2021 Feb; 81(3):405-409. PubMed ID: 33646555
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial.
Craig T; Magerl M; Levy DS; Reshef A; Lumry WR; Martinez-Saguer I; Jacobs JS; Yang WH; Ritchie B; Aygören-Pürsün E; Keith PK; Busse P; Feuersenger H; Pawaskar D; Jacobs I; Pragst I; Doyle MK
Lancet; 2022 Mar; 399(10328):945-955. PubMed ID: 35219377
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Craig TJ; Reshef A; Li HH; Jacobs JS; Bernstein JA; Farkas H; Yang WH; Stroes ESG; Ohsawa I; Tachdjian R; Manning ME; Lumry WR; Saguer IM; Aygören-Pürsün E; Ritchie B; Sussman GL; Anderson J; Kawahata K; Suzuki Y; Staubach P; Treudler R; Feuersenger H; Glassman F; Jacobs I; Magerl M
Lancet; 2023 Apr; 401(10382):1079-1090. PubMed ID: 36868261
[TBL] [Abstract][Full Text] [Related]
19. Berotralstat (BCX7353): Structure-Guided Design of a Potent, Selective, and Oral Plasma Kallikrein Inhibitor to Prevent Attacks of Hereditary Angioedema (HAE).
Kotian PL; Wu M; Vadlakonda S; Chintareddy V; Lu P; Juarez L; Kellogg-Yelder D; Chen X; Muppa S; Chambers-Wilson R; Davis Parker C; Williams J; Polach KJ; Zhang W; Raman K; Babu YS
J Med Chem; 2021 Sep; 64(17):12453-12468. PubMed ID: 34436898
[TBL] [Abstract][Full Text] [Related]
20. An expert panel's review on patients with hereditary angioedema switching from attenuated androgens to oral prophylactic therapy.
Lumry WR; Bernstein JA; Li HH; Levy DS; Jones DH; Padilla BE; Li-Mcleod J; Tachdjian R
Allergy Asthma Proc; 2024 Jan; 45(1):44-49. PubMed ID: 38151740
[No Abstract] [Full Text] [Related]
[Next] [New Search]
